Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 49 , ISSUE 2 ( April-June, 2015 ) > List of Articles

CASE REPORT

Successful Treatment of a Complicated Case of Neuroleptic Malignant Syndrome with a Higher Dose of Bromocriptine and Lorazepam

Rajesh Kashyap

Citation Information : Kashyap R. Successful Treatment of a Complicated Case of Neuroleptic Malignant Syndrome with a Higher Dose of Bromocriptine and Lorazepam. J Postgrad Med Edu Res 2015; 49 (2):88-90.

DOI: 10.5005/jp-journals-10028-1153

Published Online: 01-03-2017

Copyright Statement:  Copyright © 2015; The Author(s).


Abstract

How to cite this article

Sharma R, Kashyap R. Successful Treatment of a Complicated Case of Neuroleptic Malignant Syndrome with a Higher Dose of Bromocriptine and Lorazepam. J Postgrad Med Edu Res 2015;49(2):88-90.


PDF Share
  1. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003;169(5): 439-442.
  2. Neuroleptic malignant syndrome. Br J Anaesth 2000;85(1):129-135.
  3. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat 2006;2(2):235-240.
  4. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust NZ J Psychiatry 1999;33(5):650-659.
  5. The neuroleptic malignant syndrome: report of three cases. Ind J Psychiatry 1996;38(2): 100-103.
  6. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164(6):870-876.
  7. Neuroleptic malignant syndrome caused by combination of risperidone and lithium in a patient with multiple medical comorbidities. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(5):1147-1148.
  8. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004;22(2):389-411.
  9. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 28(4):530-535.
  10. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142(10):1137-1145.
  11. Clozapine associated neuroleptic malignant syndrome followed by catatonia: a case report. Turk Psikiyatri Dergisi 2013;24(4):140-144.
  12. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics 2009;50(1):8-15.
  13. Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry 1995;58(3):271-273.
  14. Risk factors for neuroleptic malignant syndrome: a casecontrol study. Arch Gen Psychiatry 1989;46(10):914-918.
  15. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. Ann Pharmacother 2005;39(6):1131-1135.
  16. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 1986;6(5):257-273.
  17. Central dopamine hypoactivity and the pathogenesis of the neuroleptic malignant syndrome. Psychiatr Ann 2000;30(5):363-374.
  18. Neurochemistry of thermoregulation: two negatives make a positive. Brain Res Bull 1999;50(5,6):453-454.
  19. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992;31(6):1161-1164.
  20. The neuroleptic malignant syndrome. J Clin Psychiatr 1980;41(3):79-83.
  21. Neuroleptic malignant syndrome: successful treatment with bromocriptine. J Amer Med Assoc 1983;249(3):386-388.
  22. Neuroleptic malignant syndrome: a case report. J Postgrad Med 1991;37(3):168-170.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.